Atelosteogenesis Type III (AO3)

Atelosteogenesis type III (AO3) is a very rare genetic condition that affects how bones form before birth. Babies are usually born with very short arms and legs, joints that can dislocate (hips, knees, elbows), and feet that turn inward and upward (clubfeet). Some bones—especially in the spine, ribs, pelvis, and long bones—may be under-developed or partly missing. The face may look different (for example, a cleft palate may be present). AO3 is caused by changes (variants) in a gene called FLNB, which makes a protein (filamin-B) that helps cells sense shape and mechanical forces during bone and cartilage growth. AO3 is generally considered an autosomal dominant disorder; most cases happen de novo (new in the child, not inherited), and survival varies from severe perinatal disease to longer survival with intensive care and surgery. NCBI+4MedlinePlus+4MedlinePlus+4

Atelosteogenesis type III (AO3) is a very rare genetic condition that affects how bones form before birth. Babies with AO3 have very short arms and legs, multiple joint dislocations, and under-developed bones in the spine, ribs, pelvis, and limbs. The chest (rib cage) is often small and stiff, which makes breathing difficult. Many affected babies die before or soon after birth because their lungs cannot work well in a very small chest. A few children can live longer with intensive medical support, but they often continue to have breathing problems. AO3 is part of a wider family of disorders caused by changes (variants) in a gene called FLNB, which tells the body how to make the protein filamin B—a key building block that helps growing cartilage cells keep their shape and turn into bone. MedlinePlus+2MedlinePlus+2

---

Other names

• AO3 / AOIII / Atelosteogenesis type 3

• FLNB-related atelosteogenesis

• Sometimes grouped within the FLNB-related disorder spectrum, which also includes Larsen syndrome, atelosteogenesis type I, and boomerang dysplasia. NCBI+1

---

Types

Doctors use “types” to separate related bone-growth conditions that look similar but have different typical patterns on exam and X-ray:

1. Atelosteogenesis type I (AOI) – usually lethal at birth; severe short limbs, joint dislocations, and very poor bone formation.

2. Atelosteogenesis type II (AOII) – also severe; historically called “neonatal osseous dysplasia I.”

3. Atelosteogenesis type III (AO3) – the focus of this guide; severe short limbs and multiple dislocations with specific X-ray features. Some infants may survive longer with supportive care.
   All three are FLNB-related conditions and sit on a spectrum with Larsen syndrome and boomerang dysplasia. SpringerLink+1

Within AO3, doctors sometimes talk about clinical patterns rather than formal subtypes:

• Perinatal-lethal pattern (most common): death before or shortly after birth due to respiratory failure.

• Early-survival pattern (rare): survival beyond the newborn period with intensive airway and breathing support; ongoing chest and airway weakness is typical. MedlinePlus+1

AO3 is caused by a pathogenic variant (harmful change) in the FLNB gene. FLNB makes filamin B, a protein that links the cell’s internal skeleton to signals from outside the cell. In growing cartilage (the “soft bone” that later hardens), filamin B helps cells keep their shape and respond to mechanical forces so that bones lengthen and harden correctly. When FLNB is changed, chondrocytes (cartilage cells) cannot organize their inner scaffolding properly. Bones become short and poorly modeled, and joints dislocate easily. The chest stays small, so lungs cannot expand well. AO3 is inherited in an autosomal dominant way, but most cases happen de novo (as a new change in the child), so parents usually do not have the condition. NCBI+2PubMed+2

---

Causes

AO3 has one direct biological cause: a pathogenic FLNB variant. Below are 20 cause-related factors and mechanisms that either create that cause (how the variant arises) or shape how the disease appears (why features vary). I describe each briefly in plain English so it is clear and honest.

1. Pathogenic FLNB variant – the root cause; disrupts filamin B function in cartilage. NCBI

2. Autosomal dominant inheritance – one changed copy of FLNB is enough to cause AO3. NCBI

3. De novo mutation – many variants arise newly in the child; parents are unaffected. NCBI

4. Mosaicism in a parent – a parent can carry the variant in some cells only, increasing recurrence risk even if they look unaffected. (Recognized in FLNB spectrum.) NCBI

5. Missense variants in key FLNB domains – changes in functional “hotspots” can drive severe phenotypes such as AO3. ScienceDirect

6. Effects on actin binding/cross-linking – filamin B cannot link the actin network properly, upsetting cell shape and signaling. ScienceDirect

7. Defective chondrocyte mechanotransduction – growth-plate cells fail to sense and respond to mechanical forces needed for bone elongation. ScienceDirect

8. Abnormal endochondral ossification – the normal conversion of cartilage to bone is incomplete (“atelosteogenesis” literally means “incomplete bone formation”). NCBI

9. Disharmonious skeletal maturation – bones grow unevenly; some parts are very small or poorly shaped. NCBI

10. Poor modeling of long bones – long bones look broad, bent, or irregular on X-rays. NCBI

11. Vertebral segmentation defects – blocks, fusions, or abnormal vertebral shapes contribute to a small, stiff torso. NCBI

12. Underdeveloped ribs – a small rib cage leads to lung under-development and breathing failure. MedlinePlus

13. Multiple joint dislocations – unstable connective tissues and abnormal bone shape allow joints to slip out easily. MedlinePlus

14. Clubfeet and limb malalignment – abnormal bone patterning and joint laxity deform the feet and limbs. MedlinePlus

15. Cervical spine instability – malformed vertebrae at the neck increase risk during handling or anesthesia. MalaCards

16. Airway weakness (tracheomalacia/bronchomalacia) – floppy airways cause apnea and infections in survivors. MedlinePlus

17. Possible cleft palate/hearing problems within FLNB spectrum – reported in FLNB-related disorders and may be seen in some AO3 cases. NCBI

18. Genotype-phenotype spectrum – the exact FLNB change can shift the picture toward Larsen syndrome or boomerang dysplasia rather than classic AO3. NCBI

19. Sporadic occurrence worldwide – AO3 is ultra-rare everywhere; most cases are single families or isolated cases. MalaCards

20. Not caused by pregnancy actions – there is no evidence that diet, medicines, or infections in pregnancy cause AO3 when FLNB is normal. (This is an inference from the monogenic etiology described in reviews.) NCBI

---

Common signs and symptoms

1. Very short arms and legs (severe limb shortening). Arms and legs are much shorter than expected at birth. Orpha

2. Multiple joint dislocations. Hips, knees, and elbows commonly dislocate; joints are unstable from birth. MedlinePlus

3. Clubfoot (talipes). Feet turn inward and upward; splints alone rarely correct it because the bones are abnormal. MedlinePlus

4. Small, stiff chest. A narrow rib cage limits lung growth and movement. MedlinePlus

5. Breathing failure in the newborn period. Many babies die before or soon after birth due to respiratory insufficiency. MedlinePlus

6. Weak or floppy airways (airway malacia). Survivors may have apnea and frequent chest infections. MedlinePlus

7. Abnormal spine bones (vertebral anomalies). Blocks, fusions, or misshapen vertebrae are typical on X-ray. NCBI

8. Poorly modeled long bones. Long bones can look broad, bent, or “unfinished” on imaging. NCBI

9. Characteristic facial differences. “Dysmorphic facies” are described in medical summaries, though features vary. Orpha

10. Pelvic bone under-development. The pelvis may be small or irregular, adding to hip instability. MedlinePlus

11. Hand and foot bone differences. Carpal, tarsal, and finger/toe bone changes are reported. NCBI

12. Feeding difficulties. Weakness and breathing problems can make feeding hard in newborns. MalaCards

13. Neck (cervical) instability. The top of the spine can be unstable, increasing risk with handling or surgery. MalaCards

14. Developmental delay in survivors. Low oxygen from airway problems may affect learning and language. MedlinePlus

15. High newborn mortality with rare longer survival. Survival beyond the neonatal period is uncommon but possible with intensive support. MedlinePlus

---

Diagnostic tests

A) Physical examination

1. Newborn clinical exam. Doctors check body length, head size, chest size, and limb proportions; severe limb shortening with dislocations suggests AO3 or related disorders. Orpha

2. Chest and breathing assessment. Rapid breathing, retractions, or low oxygen point to a small, stiff chest and pulmonary under-development. MedlinePlus

3. Joint stability check. Gentle maneuvers show dislocated hips/knees/elbows; persistent instability is typical. MedlinePlus

4. Spine and neck exam. Short trunk, limited motion, and possible neck instability raise concern for vertebral malformations. NCBI

5. Facial, hands, and feet inspection. Dysmorphic features, clubfeet, and hand/foot differences support a skeletal dysplasia diagnosis. Orpha

B) Manual (bedside) tests

6. Hip dislocation maneuvers (Ortolani/Barlow). These bedside tests detect unstable or dislocated hips in newborns. (Used broadly in dysplasias with hip involvement.) MedlinePlus

7. Range-of-motion mapping. Careful, gentle mapping of joint movement documents severity and guides orthopedics. PubMed

8. Airway assessment (bedside). Observation for stridor, pauses in breathing, or airway collapse guides urgent care. MedlinePlus

9. Feeding and swallow screen. Early bedside checks look for aspiration in infants with chest weakness. MalaCards

C) Laboratory and pathological tests

10. Targeted FLNB genetic testing (postnatal). Confirms the diagnosis by finding a pathogenic variant in FLNB. Next-generation sequencing of the coding region is standard. NCBI

11. Prenatal genetic testing (CVS or amniocentesis). If ultrasound suggests AO3 or there is family history, fetal DNA can be tested for FLNB variants. NCBI

12. Exome/genome sequencing. Used when the exact cause is unclear, to detect FLNB or other skeletal-dysplasia genes. (Part of modern dysplasia work-ups.) NCBI

13. Genetic counseling documentation. Records inheritance, de novo risk, and recurrence risk for parents and future pregnancies. NCBI

14. Rule-out labs for differentials. While AO3 is genetic, clinicians may order metabolic or infection labs to exclude other causes of short-limb and chest problems in the newborn. (General clinical practice; definitive AO3 remains genetic.) NCBI

D) Electrodiagnostic and physiologic tests

15. Pulse oximetry and blood gases. Check oxygen and carbon dioxide levels to judge breathing failure. (Essential in small-chest disorders.) MedlinePlus

16. Polysomnography (sleep study) in survivors. Measures apnea from airway weakness; guides ventilatory support. MedlinePlus

17. Cardiorespiratory monitoring. Continuous ECG-oximetry trend data help manage instability in neonatal intensive care. (Standard in severe dysplasias with respiratory compromise.) MedlinePlus

E) Imaging tests

18. Prenatal ultrasound (2D/3D). Shows very short limbs, small chest, and joint dislocations before birth; prompts genetic testing. Obstetrics & Gynecology

19. Fetal MRI (selected cases). Helps assess lung size and airway or spine anatomy when ultrasound is limited. (Used in complex skeletal dysplasias.) Obstetrics & Gynecology

20. Postnatal skeletal survey (X-rays of the whole skeleton). The key test after birth: reveals poorly modeled long bones, vertebral fusions, and other classic AO3 features. Orpha+1

21. Chest radiograph. Measures rib cage size and shape; helps monitor lung problems. MedlinePlus

22. Cervical spine imaging (lateral and flexion-extension views when safe). Detects neck instability and malformed vertebrae that raise care risks. MalaCards

23. CT of airway or spine (selected). Clarifies airway collapse or complex bony anatomy when planning surgery or ventilation. PubMed

24. Echocardiography (selective). Not a defining feature, but doctors may screen the heart in critically ill newborns with chest insufficiency. (General NICU practice.) MedlinePlus

25. Follow-up radiographs in survivors. Track bone growth, joint alignment, and surgical results over time. PubMed

Non-pharmacological treatments (therapies & others)

Note: These are supportive measures chosen case-by-case by your clinical team. They aim to protect breathing, feeding, growth, joint function, and comfort while planning staged orthopedic care.

1. Family-centered neonatal intensive care
   Purpose: Stabilize breathing and circulation, prevent complications, and plan early imaging and genetics.
   Mechanism: Care bundles (thermal control, non-invasive ventilation when feasible, cautious intubation if needed, gentle handling to avoid fractures or dislocations, early radiographs plus genetic testing). Neonatologists coordinate airway, nutrition, pain control, and transfers to a tertiary skeletal dysplasia center. NCBI+1

2. Respiratory support & airway planning
   Purpose: Support gas exchange if chest wall or airway anomalies impair breathing.
   Mechanism: Non-invasive ventilation or carefully titrated mechanical ventilation; airway assessment for potential difficult intubation; strategies to reduce barotrauma in small, stiff chests. Pulmonology and anesthesia collaborate on extubation and sleep-disordered breathing surveillance. PubMed

3. Feeding, swallowing, & nutrition therapy
   Purpose: Ensure safe feeding and adequate growth; prevent aspiration.
   Mechanism: Speech-language pathology evaluates suck–swallow–breath coordination; thickened feeds or alternative routes (NG/G-tube) if unsafe; dietitians tailor high-calorie formulas; micronutrient optimization supports bone health. NCBI

4. Early orthopedic positioning & joint protection
   Purpose: Reduce dislocation risk and soft-tissue contractures while awaiting definitive surgery.
   Mechanism: Customized splints, careful positioning, and handling protocols; avoidance of forceful maneuvers; serial monitoring of hips, knees, elbows, and feet for stability. PubMed

5. Serial casting for clubfoot (Ponseti-style, modified)
   Purpose: Gradually correct clubfoot deformity to improve foot alignment for bracing or future surgery.
   Mechanism: Gentle, staged manipulations with well-padded casts acknowledging bone fragility and joint laxity in AO3; bracing to maintain correction. PubMed

6. Physiotherapy (developmental & respiratory)
   Purpose: Maintain range of motion, prevent contractures, and support motor milestones and secretion clearance.
   Mechanism: Low-load, pain-free stretching, positioning, supported sitting/standing programs when safe; airway clearance techniques as indicated; home exercise instruction for caregivers. PubMed

7. Occupational therapy for daily living skills
   Purpose: Optimize function with limb shortening and joint instability.
   Mechanism: Adaptive strategies for feeding, dressing, and play; custom supports; caregiver training; environmental modifications for safe mobility and positioning. PubMed

8. Orthotic management (custom bracing)
   Purpose: Improve joint alignment and stability; reduce pain; support mobility aids.
   Mechanism: AFOs/KAFOs or upper-limb splints tailored to limb proportions and dislocations; periodic refitting as the child grows. PubMed

9. Assistive mobility devices
   Purpose: Enable safe mobility and participation.
   Mechanism: Strollers/wheelchairs with postural supports; lightweight walkers or standing frames; growth-friendly seating systems to protect spine and hips. PubMed

10. Growth-friendly spinal surveillance
    Purpose: Detect progressive scoliosis/kyphosis and cervical instability early.
    Mechanism: Scheduled radiographs and clinical exams; MRI if cord compression suspected; bracing considered case-by-case; escalate to surgical consultation when thresholds are met. BioMed Central

11. Skin and pressure-injury prevention
    Purpose: Protect fragile skin and prevent sores under casts/braces and during long hospital stays.
    Mechanism: Frequent skin checks, pressure-relief cushions, proper padding, and moisture control. PubMed

12. Pain neuroscience education & non-drug pain strategies
    Purpose: Reduce pain and anxiety, improve coping.
    Mechanism: Positioning, heat/cold (when appropriate), relaxation breathing, distraction, and caregiver-guided comfort measures; coordinate with psychology/child-life specialists. PubMed

13. Educational support & care coordination
    Purpose: Navigate complex appointments, equipment, and funding; support schooling plans.
    Mechanism: Case managers and social workers organize multidisciplinary visits and connect families with rare-disease networks and telehealth. Genetic & Rare Diseases Center

14. Genetic counseling
    Purpose: Explain diagnosis, inheritance, and recurrence risk; discuss reproductive options.
    Mechanism: Review FLNB testing results; discuss de novo vs inherited variants; offer testing to parents if appropriate; provide resources. NCBI

15. Speech therapy (cleft palate / feeding / communication)
    Purpose: Address speech resonance and feeding if a cleft palate or oral-motor challenges are present.
    Mechanism: Pre- and post-palate repair therapy, augmentative communication as needed. MedlinePlus

16. Dental & ENT surveillance
    Purpose: Manage otitis media, airway issues, and dental malocclusion that can follow craniofacial differences.
    Mechanism: Regular ENT checks, hearing screens, dental care, and timely referrals. MedlinePlus

17. Bone health fundamentals
    Purpose: Support mineralization in the context of low mobility.
    Mechanism: Adequate calories/protein, safe sunlight exposure or vitamin D per pediatric guidance, calcium from diet; weight-bearing within safety limits. (No disease-specific proof for pharmacologic bone agents in AO3.) NCBI

18. Psychosocial support & peer connection
    Purpose: Reduce caregiver stress and isolation; build resilience.
    Mechanism: Counseling, support groups, rare-disease communities, and practical training for home care. Genetic & Rare Diseases Center

19. Home safety planning
    Purpose: Prevent falls and joint injuries at home.
    Mechanism: Adaptive equipment, safe transfer techniques, and tripping-hazard reduction. PubMed

20. Transition-to-adulthood planning (for survivors)
    Purpose: Maintain continuity of orthopedic, pulmonary, and rehab care into adult services.
    Mechanism: Written transition plans, equipment updates, and vocational counseling. NCBI

---

Drug treatments

Important safety note: In AO3, medicines treat symptoms or complications (pain, spasms, reflux, infections, anesthesia needs). Doses and timing must be individualized by the child’s clinician using standard pediatric references. There is no approved drug that changes the underlying FLNB biology in AO3. NCBI

1. Acetaminophen (paracetamol) – analgesic/antipyretic for procedural and postoperative pain. Helps reduce pain without bleeding risk; schedule or as-needed per pediatric guidance; monitor total daily dose with combination products. Common effects: nausea; rare hepatotoxicity in overdose. NCBI

2. NSAIDs (e.g., ibuprofen) – adjunct for pain/inflammation after orthopedic procedures; use cautiously if renal risk, gastric irritation, or bleeding risk; avoid peri-operative periods when surgeon advises. Side effects: GI upset, renal effects. PubMed

3. Opioids (short-term, carefully titrated) – for acute postoperative pain when other measures are insufficient; careful monitoring for respiratory depression, especially with chest wall restriction. Side effects: constipation, sedation, pruritus. PubMed

4. Muscle relaxants (e.g., baclofen) – reduce painful spasm if present; start low, go slow; monitor for sedation, hypotonia. PubMed

5. Local anesthetics / regional blocks – peri-operative pain control while minimizing systemic opioids; delivered by anesthesia specialists experienced in skeletal dysplasia. Risks: local anesthetic toxicity, nerve injury (rare). PubMed

6. Antibiotic prophylaxis (peri-operative) – per local surgical protocols for bone/soft-tissue procedures to reduce infection risk. Choice guided by hospital antibiogram and procedure type. Side effects depend on agent. PubMed

7. Bronchodilators (as indicated) – if reactive airways or post-operative bronchospasm; monitor response; not routine otherwise. PubMed

8. Nebulized hypertonic saline or airway clearance adjuncts (selected cases) – to mobilize secretions in prolonged ventilation or chest infections; use per pulmonology. PubMed

9. Acid suppression (H2 blockers/PPIs) – for significant reflux that increases aspiration risk; use the shortest effective duration; consider weaning plans. Risks: altered microbiome, mineral absorption concerns with long-term PPI. PubMed

10. Stool softeners/laxatives (e.g., PEG) – manage opioid-related constipation and low-mobility bowel patterns; titrate to soft daily stools. PubMed

11. Antiemetics (e.g., ondansetron) peri-operative – reduce postoperative nausea/vomiting to protect surgical repairs and nutrition. PubMed

12. Vitamin D (per labs) and calcium (diet/supplement if needed) – support bone mineralization; correct deficiencies under pediatric supervision. (No AO3-specific efficacy trials; principle extrapolated from general bone health.) NCBI

13. Iron supplementation (if iron-deficiency anemia) – improves energy and wound healing; give only when indicated by labs. PubMed

14. Antihistamines or intranasal steroids (ENT plans) – if chronic rhinitis or otitis contributes to sleep-breathing problems; short courses under ENT guidance. PubMed

15. Topical barrier creams / wound care agents – protect skin under casts/braces and treat pressure areas. PubMed

16. Thromboprophylaxis (procedure-specific) – in older children/adults during prolonged immobilization if risk factors present; surgeon/anesthetist decide. PubMed

17. Peri-operative tranexamic acid (selected orthopedic cases) – reduce blood loss in major bone surgery when appropriate. Risk: thrombosis (rare; screen risks). PubMed

18. Antimicrobials for documented infections – treat pneumonia/soft-tissue infection guided by cultures and local guidelines; avoid unnecessary antibiotics. PubMed

19. Sleep-disordered breathing therapies (e.g., inhaled meds adjuncts; PAP devices are non-drug) – medications are limited; mainstay is device-based support with ENT input. BioMed Central

20. Avoid unproven “bone-strengthening” prescriptions – No evidence that bisphosphonates or growth hormone improve outcomes in AO3; consider only under specialist research protocols for clear indications unrelated to AO3 itself. NCBI

---

Dietary molecular supplements

Use only to correct proven deficiencies or as general nutrition support under a clinician/dietitian; none modify FLNB biology in AO3.

1. Vitamin D – Correct deficiency to support calcium absorption and bone mineralization; dose per labs and pediatric guidance; avoid excessive dosing to prevent hypercalcemia. NCBI

2. Calcium (diet first, supplement if needed) – Builds bone matrix; balance with vitamin D; too much can cause constipation or impair iron absorption. NCBI

3. Protein energy supplements – Concentrated calories/protein help wound healing and growth when feeding volume is limited; given as modular powders/liquids. PubMed

4. Iron (only if deficient) – Restores hemoglobin and supports development; monitor ferritin and transferrin saturation; avoid in inflammation without deficiency. PubMed

5. Zinc (if low) – Supports growth and wound healing; excess can lower copper. PubMed

6. Omega-3 fatty acids – May modestly reduce inflammation and support neurodevelopment; choose age-appropriate doses and watch for bleeding risk near surgery. PubMed

7. Multivitamin (age-appropriate) – “Insurance” for micronutrient gaps in selective eaters or tube-fed children; avoid megadoses. PubMed

8. Fiber supplements (as needed) – Help constipation from low mobility/opioids; titrate to effect with fluids. PubMed

9. Electrolyte solutions during illness – Prevent dehydration and support mucociliary clearance; use pediatric formulas. PubMed

10. Probiotics (selected cases) – May reduce antibiotic-associated diarrhea; pick strains with pediatric data; stop if intolerance. PubMed

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster, regenerative, or stem-cell drugs that treat AO3’s genetic cause. Any such use would be experimental and should occur only within IRB-approved research. Supportive options below do not alter FLNB biology:

1. Vaccination per schedule – Indirectly protects health by preventing infections that stress breathing/hospitalization; not disease-modifying for AO3. PubMed

2. Nutritional optimization – Adequate protein, calories, vitamin D, and minerals support tissue repair; not gene-directed therapy. NCBI

3. Physiologic osteoanabolic stimuli (safe weight-bearing) – Gentle, guided loading promotes bone health where feasible; not a drug and not disease-modifying. PubMed

4. Clinical-trial enrollment (gene/precision approaches) – If a trial emerges for FLNB-related disorders, participation may offer access to investigational agents; none are standard of care today. MDPI

5. Avoid off-label “stem-cell” clinics – No evidence for AO3; potential harm and cost; prefer regulated research programs. NCBI

6. Peri-operative blood-conservation protocols – Not regenerative drugs, but strategies like cell saver and TXA reduce transfusion need in major spine/limb surgery. PubMed

---

Surgeries

1. Clubfoot correction (Ponseti + limited release / tendon procedures)
   Procedure: Serial casts; if resistant, percutaneous Achilles tenotomy or limited soft-tissue release; bracing afterward.
   Why: Achieve plantigrade, brace-able feet for comfort and function. PubMed

2. Joint stabilization (hips/knees/elbows) and tendon balancing
   Procedure: Open or minimally invasive reduction, capsulorrhaphy, osteotomies as needed; staged over years.
   Why: Improve joint congruence, reduce pain, and enable bracing or mobility devices. PubMed

3. Spine surgery (deformity correction / growth-friendly constructs)
   Procedure: Bracing first; if progressive deformity or neurological risk, posterior instrumentation (growth-friendly in young children) with careful anesthesia.
   Why: Prevent cord compression, improve sitting balance and breathing mechanics. BioMed Central

4. Cleft palate repair (if present)
   Procedure: Palatoplasty at standard timing with airway planning.
   Why: Improve feeding, speech, and reduce otitis media. MedlinePlus

5. Airway procedures (selected cases)
   Procedure: ENT interventions (e.g., adenoid/tonsil surgery or airway stabilization) when obstructive sleep apnea or structural airway issues persist.
   Why: Improve oxygenation, ventilation, growth, and neurodevelopment. BioMed Central

---

Preventions

1. Safe handling to avoid joint dislocation/fracture; always support limbs. PubMed

2. Up-to-date vaccinations (child and household). PubMed

3. Regular pulmonary and ENT follow-up to catch airway/sleep issues early. BioMed Central

4. Skin checks under casts/braces to prevent sores. PubMed

5. Dental hygiene and hearing screens if cleft-related risks. MedlinePlus

6. Nutrition plans to maintain growth and bone health. NCBI

7. Home fall-prevention and adaptive equipment. PubMed

8. Regular spine/hip surveillance to act before deformities worsen. BioMed Central

9. Peri-operative checklists at centers experienced in skeletal dysplasia. PubMed

10. Genetic counseling for family planning. NCBI

---

When to see doctors

• Breathing problems: fast breathing, retractions, cyanosis, pauses, noisy sleep—seek urgent care. PubMed

• Feeding trouble/poor weight gain or frequent coughing with feeds—call your team; aspiration risk. PubMed

• Unusual limb pain/swelling after minor handling—possible fracture/dislocation—get orthopedic review. PubMed

• New or worsening spinal curvature, neck pain, limb weakness, or numbness—urgent spine evaluation. BioMed Central

• Fever, wound redness, or drainage after surgery—possible infection. PubMed

• Any planned surgery or anesthesia—ensure the team is familiar with skeletal dysplasia needs. PubMed

---

What to eat and what to avoid

What to prioritize:

• Balanced, calorie-adequate meals with protein (eggs, fish, legumes), calcium-rich foods (dairy, fortified alternatives), and vitamin D (fortified foods; safe sun; supplements if prescribed).

• Fiber and fluids to prevent constipation, especially with low mobility or opioid use.

• Small, frequent feeds or calorie-dense formulas if volume limited; follow a dietitian’s plan. NCBI+1

What to limit/avoid:

• Sugary drinks and ultra-processed snacks that displace nutrient-dense foods.

• High-dose supplements without labs/medical advice.

• New foods or textures that increase choking/aspiration risk without speech-therapy clearance in infants with swallowing concerns. PubMed

---

Frequently asked questions

1. What causes AO3?
   Changes in the FLNB gene alter a protein that helps bone and cartilage cells sense mechanical forces; this disrupts normal skeletal growth. NCBI+1

2. Is it inherited?
   AO3 follows autosomal dominant inheritance, but many cases are de novo (new in the child). A genetic counselor can clarify risks for future pregnancies. Orpha+1

3. How is AO3 diagnosed?
   Clinical exam + skeletal X-rays + FLNB genetic testing confirm the diagnosis. NCBI

4. How severe is it?
   Severity varies. Some newborns have life-threatening breathing problems; others survive with intensive and ongoing orthopedic and pulmonary care. NCBI

5. Is there a cure or gene therapy?
   No approved therapy currently changes FLNB in people. Care is supportive; research is ongoing in FLNB biology. MDPI

6. What surgeries are common?
   Clubfoot correction, joint stabilization, and sometimes spine surgery; cleft palate repair if present. Timing is individualized. PubMed+1

7. Will my child walk?
   Some children may achieve assisted mobility or short-distance ambulation with bracing and devices; others may primarily use wheelchairs. Early rehab helps maximize function. PubMed

8. How do we prevent dislocations?
   Gentle handling, protective bracing, and avoiding forceful maneuvers; plan lifts/transfers with therapists. PubMed

9. Are bones brittle like in osteogenesis imperfecta?
   AO3 involves abnormal modeling and dislocations more than classic bone fragility, but fractures can still occur—use careful handling. NCBI

10. What about school and play?
    OT/PT will suggest adaptive seating, writing aids, and safe activities to support participation. PubMed

11. Is bisphosphonate treatment used?
    There’s no evidence it improves AO3 outcomes. Consider only for separate, clearly defined bone-density indications under a specialist. NCBI

12. Will my child need oxygen or ventilator support?
    Some infants do, especially early on. Pulmonology tailors support and re-evaluates as the child grows. PubMed

13. Can we join a community?
    Yes—rare-disease networks and GARD resources connect families and share practical tips. Genetic & Rare Diseases Center

14. What specialists should be on our team?
    Neonatology, orthopedics, genetics, pulmonology/ENT, anesthesia, rehabilitation (PT/OT/SLP), nutrition, dentistry, and social work. PubMed

15. How often are checkups?
    Early life: frequent. Later: regular orthopedic/spine imaging, pulmonary/ENT reviews, rehab, and dental/hearing checks—your team will set a schedule. BioMed Central

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 25, 2025.